Kornimate/medical-research-clean huggingface dataset:
effects of 2 different doses of pantoprazole on gastric ph and recurrent bleeding in patients who bled from peptic ulcers

Conditions: Peptic Ulcer Hemorrhage

Summary: endoscopic treatment of bleeding peptic ulcers is effective to prevent rebleeding. adjuvant medical treatment to increase gastric ph may further decrease rebleeding. recent studies on potent acid suppression by proton pump inhibitors (ppi) demonstrated the efficacy in preventing rebleeding. lau demonstrated that high dose intravenous infusion of omeprazole decreased rebleeding in peptic ulcers with stigmata of recent hemorrhage. there is little data regarding the effect of pantoprazole on bleeding peptic ulcers. furthermore, the optimal dose of ppi is unknown. few studies have included measurement of gastric ph in addition to clinical outcome. this study compares the effect of two doses of intravenous pantoprazole with no acid suppression in bleeding peptic ulcers after endoscopic therapy. in addition to the usual clinical endpoints, gastric ph is monitored to study the relation of ph elevation and the clinical outcome.


Eligibility criteria:
inclusion criteria: * patients presenting with upper gastrointestinal bleeding with upper endoscopy showing a bleeding peptic ulcer with major stigmata of haemorrhage and after successful endoscopic haemostasis. exclusion criteria: * previous gastrectomy and vagotomy * patient taking warfarin * intake of anti-secretory drugs in the previous 48 hours
radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in bulky early-stage cervical cancer (kgog 1029)

Conditions: Cervical Cancer

Summary: to compare 5-year overall survival between patients who undergo radical hysterectomy followed by tailored adjuvant therapy and patients who receive primary chemoradiation therapy in figo stage ib2 and iia2 cervical cancer


Eligibility criteria:
inclusion criteria: * previously untreated, histologically confirmed cervical cancer * figo stage ib2 and iia2 disease * one of following histologic types 1. squamous cell carcinoma 2. adenocarcinoma 3. adenosquamous carcinoma * gynecologic oncology group performance status: 0-2 * adequate organ function 1. bone marrow: wbc \> 3000/mm3, anc ≥ 1,000/mm3, platelet ≥ 100\*103/mm3, hemoglobin ≥ 10g/dl 2. kidney: creatine \< 1.25 \* upper normal limit 3. liver: ast, ant \< 3 \* upper normal limit, total bilirubin \< 1.5 mg/mm3 * patient who have singed an approved informed consent exclusion criteria: * patients with cervical cancer who have received any previous radiation or chemotherapy * neuroendocrine carcinoma of uterine cervix * occult cervical cancer which was found after simple hysterectomy * para-aortic nodal involvement (\> 10 mm short axis diameter on pretreatment imaging study) * history of other invasive malignancies, with the exception of non-melanoma skin cancer, in situ melanoma and thyroid cancer, who had (or have) no evidence of the other cancer present within the last 5 years * serious illness or medical condition that precludes the safe administration of the trial treatment including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * prior diagnosis of crohn's disease or ulcerative colitis * neurologic or psychiatric disease * patients who are pregnant or lactating

Keywords: cervical cancer bulky early-stage locally advanced radical hysterectomy concurrent chemoradiation therapy
rct-evaluation of retzius-sparing robotic prostatectomy

Conditions: Prostate Cancer; Urinary Incontinence

Summary: prospective randomized blinded rct comparing transdouglas prostatectomy to classical transperitoneal anterior radical prostatectomy

we will evaluate functional urinary and sexual recovery, oncologic outcomes and postoperative complications in patients over a follow up period of 12 months

Eligibility criteria:
inclusion criteria: * indication for radical prostatectomy * \>18 years old * literate * preoperatively continent * informed signed consent for study exclusion criteria: * ct4-cancer * withdrawl of consent to study
risk factors, prognosis and prediction models for placenta accreta without prior cesarean section

Conditions: Placenta Accreta Spectrum

Summary: 1. identify the risk factors for placenta accreta spectrum (pas) disorders in women without prior caesarean section (cs). 2. clarify the prognostic factors of the disease and explore individualized treatment options to improve the prognosis of patients with this type of disease; 3. use the cohort's biological sample database to conduct serology, cytology, and histology studies to explore the abnormal uterine immune microenvironment and the impact on uterine spiral artery remodeling in non-scar uterine-placenta accreta disease.

the placenta accreta spectrum (pas) is defined as abnormal placental trophoblast adherence with a wide range of myometrial invasion. it is a serious pregnancy complication that can lead to severe postpartum hemorrhage, which may necessitate hysterectomy, and could ultimately lead to maternal death.previous studies have shown that women with the highest risk of pas disorders are those with a prior cesarean section (cs) who present in the second trimester of pregnancy with any degree of placenta previa or low-lying placenta.pas patients without prior cs represent about one-third of the entire pas population.the strategy to identify at-risk patients without a prior cs has yet to be defined. this may lead to under identification of pas patients without prior cs and create a missed opportunity to plan the delivery and improve prognosis in these women. established risk factors distinct from prior cs delivery include in vitro fertilization (ivf), intrauterine implants, endometritis, uterine artery embolization manual placental removal, uterine malformation, adenomyosis, submucosal fibroids, smoking, maternal weight, maternal age, parity, and multifetal pregnancy. large clinical studies focusing on pas disorders in women without prior cs are, indeed, scarce.this study aims to explore the risk factors and prognosis of pas without a history of cesarean section and try to establish the prediction model.

Eligibility criteria:
inclusion criteria: * pregnant women without prior cesarean section * pregnant women who had prenatal check-ups and gave birth at the obstetrics department of peking university third hospital from january 1, 2023 to december 31, 2024 exclusion criteria: * pregnant women who did not terminate pregnancy at the obstetrics department of peking university third hospital * pregnant women who gave birth at \<28 weeks.
asthma education using child life services and an asthma-based computer game

Conditions: Asthma

Summary: this is a single center pilot study designed to evaluate the effectiveness of an asthma education program in the pediatric emergency department. asthma has reached epidemic proportions. nine million american children are affected in the united states alone. this problem has increased 75% from 1980 to 1994, with a staggering 160% increase seen in children less than five years old.1 the american lung association has targeted this overwhelming problem on both national and local levels. asthma impacts american communities who differ geographically, culturally, ethnically and by lifestyle, and as a result will present with different obstacles. the primary objectives are: to determine whether this educational intervention (through interactions with a child life specialist and using the asthma based computer game) in the pediatric ed can influence children's \[and care givers'\] knowledge and understanding of the disease process and treatment, and to improve asthma self-management and decrease morbidity by decreasing ed use and hospitalization. a secondary objective is to introduce the child life specialist as an effective asthma educator and further strengthen the health care team. the target population will be recruited from the pediatric emergency department. we anticipate this study to recruit over a one year period and have a one year follow up with an anticipated enrollment of 64 children and families. there will be three child life specialist involved in this program. after consent has been obtained, the child and parent will complete questionnaires (focusing on asthma knowledge, quality of life, and perception of asthma) and then a laptop will be provided to access the asthma based computer game. during the child's ed visit the child life specialist will have opportunities to open communication to address barriers or concerns, and reinforce material provided by the game. through these interactions, the importance of communication between the child, parent and healthcare provider is highlighted. the family will be given information to access the computer game via the internet. follow up phone calls or e-mails will occur at 6 months, 9 months, and 12 months which will entail completing questionnaires. the questionnaires uses validated questions along with questions from the material covered through this asthma education study.


Eligibility criteria:
inclusion criteria: * age between six to eighteen years old * diagnosis of asthma exclusion criteria: * refused to participate in the study * unable to understand or respond to questions * if participants are not english speaking
plasma ebv dna monitoring in post-treatment npc patients

Conditions: Nasopharyngeal Carcinoma; NPC; EBV; Radiotherapy

Summary: continuous regular monitoring of plasma ebv dna in nasopharyngeal carcinoma (npc) after treatment have rarely been investigated. the investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in npc patients after curative treatment.

the investigators enrolled 441 npc patients who had finished finished curative radiotherapy with/without chemotherapy and no recurrence/metastasis before entry this study from five hospitals in taiwan. blood samples were collected on the day of enrollment and monitored once every 2-3 months for plasma ebv dna measurement. after long-term observation, we analyze the impact of continuous plasma ebv dna monitoring on the early dection of tumor relapse and do risk grouping for survival analyses according to the blood test results.

Eligibility criteria:
inclusion criteria * histologically-proven nasopharyngeal carcinoma without distant metastasis (m0) at initial presentation * finished curative radiotherapy (with/without chemotherapy) within 3 years exclusion criteria * no occurrence of documented recurrence/metastasis before entry

Keywords: nasopharyngeal carcinoma npc ebv radiotherapy plasma epstein-barr virus dna
a study for patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to test the hypothesis that 1 or more dose levels of ly2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.


Eligibility criteria:
some inclusion criteria: * patients must have a diagnosis of schizophrenia as defined in diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) (disorganized, 295.10; catatonic, 295.20; paranoid, 295.30; residual, 295.60; or undifferentiated, 295.90) and confirmed by the structured clinical interview for dsm-iv (scid). * patients must meet the following psychopathologic severity criteria at visit 1: brief psychiatric rating scale (bprs) total score, extracted from the positive and negative syndrome scale (panss), of at least 45 (18-item version, in which 1 indicates "absent" and 7 indicates "severe"). in addition, item scores of at least 4 (moderate) will be required on 2 of the following bprs items: conceptual disorganization, suspiciousness, hallucinatory behavior, and/or unusual thought content. * patients must receive a rating of 4 (moderately ill) or greater on the clinical global impression-severity (cgi-s) scale at visit 1. * patients in whom, in the opinion of the investigator, a switch to another antipsychotic medication or initiation of an antipsychotic medication is acutely indicated. some exclusion criteria: * patients in whom treatment with olanzapine or placebo is relatively or absolutely clinically contraindicated. * patients who have a history of inadequate response to an adequate treatment trial with olanzapine, in the opinion of the investigator. * patients who have received treatment with olanzapine within 6 weeks prior to visit 1. * patients who have received treatment with clozapine at doses greater than 200 mg daily within 12 months prior to visit 1, or who have received any clozapine at all during the month before visit 1. * patients who have a history of an inadequate response, in the opinion of the investigator, to 2 or more adequate antipsychotic medication trials of at least 8 weeks duration in the past 12 months prior to visit 1. * patients with acute, serious, or unstable medical conditions, including (but not limited to) inadequately controlled diabetes (hemoglobin a1c (hba1c) 8%), severe hypertriglyceridemia (fasting triglycerides 5.6 mmol/l, recent cerebrovascular accidents, serious acute systemic infection or immunologic disease, unstable cardiovascular disorders (including ischemic heart disease), malnutrition, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, or hematologic diseases.
a multi-centric clinical trial in china for skin diseases intelligent diagnosis and treatment system

Conditions: Skin Diseases; Artificial Intelligence; Augmented Reality; Medical Imaging

Summary: in response to clinical needs, infrared multi-spectral images are combined with traditional clinical images and other multi-modal data to build a more efficient intelligent auxiliary diagnosis system and intelligent equipment for skin health and diseases, including skin lesions automatically segmentation on skin diseases images, automatically design surgical margin and planning for skin tumor surgery.

database: relying on the preliminary foundation, build the first standardized infrared multispectral image database of skin diseases, and further integrate other medical images and medical history texts to iterate into a large multimodal skin disease database. model: design a deep learning network based on multi-scale and multi-level. the collaborative attention learning network realizes the collaborative representation of multi-modal data at the feature level, builds a multi-modal skin disease auxiliary diagnosis model, and realizes breakthroughs in algorithms. develop the segmentation network of skin lesions and model for surgery planning, including surgical margin design and navigation of intraoperative sampling. system: propose an artificial intelligence system combined with the real-time augmented reality to assist dignosis and surgery for skin diseases. equipment: based on the self-developed high-performance system, construct and assemble infrared multi-spectral skin disease auxiliary diagnosis equipment and multifunctional device for skin tumors surgery.

Eligibility criteria:
inclusion criteria: * informed consented. * with a diagnosis of skin disease made by at least 3 dermatologists. * without life-threatening risk to intervention. * requires surgical treatment (for devices). exclusion criteria: * having difficulties to follow-up. * poor general condition.

Keywords: augmented reality skin tumor surgery plan and navigation dignosis and treatment
feasibility study on the use of redormin®500 on day-time cognition

Conditions: Sleep Disorders, Circadian Rhythm; Cognitive Dysfunction

Summary: randomized, double-blind, parallel groups, placebo-controlled, baseline/run-in period of 21 days followed by trial period of 21 days, digital phenotyping (sleep, cognitive/psychological parameters and hrv). the aim of this study is to determine the feasibility of investigating the effects of redormin® 500 on day-time cognition and to assess psychological parameters (subjective cognitive performance, tiredness, mood, stress level, quality of life, motivation), in people with occasional sleep problems. sleep tracking data will be collected using consumer devices of the charge series by fitbit.

the overall objective of this study is to evaluate the feasibility of the planned study design and to evaluate the effect of redormin® 500 on cognitive performance (reaction time, working memory) and psychological parameters with daily measures. the primary objective of this study is to evaluate the feasibility of the study design to be able to design a confirmatory study. the secondary objectives are to assess the influence of redormin® 500 on cognitive performance (reaction time, working memory) and psychological parameters (subjective cognitive performance, stress levels, tiredness, mood, quality of life, and motivation; all of these measures with reference to the current day) with daily measures in the evening, and on sleep parameters and heart rate variability (hrv) as an objective measure for the stress level during day as assessed by the fitbit tracker. safety objectives: safety will be evaluated by obtaining and analysing adverse events during run-in period and treatment period.

Eligibility criteria:
inclusion criteria: * healthy * male or female * age: 18-65 years old * occasional sleep problems (in average 1-2 nights per week, psqi-score \>5) with accompanying subjective cognitive problems (in average at least on one day per week) in the last month * fluent in german * able and willing to give written informed consent and comply with the requirements of the study protocol exclusion criteria: * dsm-v diagnosis of insomnia * history of neurologic disorder * current psychiatric disorder * presence of moderately severe or severe depressive disorder (phq-9 ≥ 15) * current chronic intake of prescription drugs with psychotropic effects * current intake of otc drugs for sleep or mood problems * presence of pain condition * diabetes mellitus * coronary heart disease
effectiveness of interfaces program to promote work ability of people with disabilities

Conditions: Disabilities Mental; Disabilities Physical

Summary: the objectives of the study is to evaluate the effectiveness of "the interfaces program" to promote person's components, performance and improving the work environment of people with disabilities.

people with disabilities experience many barriers in trying to integrate into the competitive market. the barriers may be result of the unique characteristics of the individual (characteristics of the disability, occupational history, work self-efficacy, etc.), the characteristics of the occupation and occupational performance (characteristics of the job and the job demands) and environmental barriers (accessibility, discrimination, stigma and lack of opportunities, etc.). the main response to the integration problems of people with disabilities in the world of work is supported employment service. supported employment focuses primarily on placement of the individual and do not relate to barriers relating to the individual's ability to develop a career. the present study examines the effectiveness of a new intervention program "the interfaces program " aiming to promote career development process among people with disabilities working in the competitive market. the program presents an integration of the person-environment-occupation-performance (peop) model and lead career development theories. the ultimate goal of this study is to examine the effectiveness of the "interfaces program" by examining its impact on the promotion of objective and subjective measures among people with disabilities who work and receive supported employment services.

Eligibility criteria:
inclusion criteria: * psychiatric or physical disability * 12 years of educations minimum * at least 26 score on the montreal cognitive assessment ( moca) * working at least 3 month in the open market exclusion criteria: * autistic spectrum disorder (asd) * developmental cognitive disability * alcohol or drags comorbidities

Keywords: career development, people with disabilities
deep venous thrombosis after hepatobiliopancreatic surgery

Conditions: Venous Thrombosis; Pulmonary Embolism; Hepatectomy; Pancreatectomy

Summary: to investigate the incidence of pre- and early postoperative deep venous thrombosis in patients undergoing hepatobiliopancreatic surgery, as well as potential corresponding risk factors with special attention to circulating tumor cells.

thromboembolic events are a common cause of morbidity and mortality in oncological patients. up to 20% of cancer patients suffer from venous thromboembolism (vte) induced by the underlying malignancy itself. oncologic gastrointestinal surgery is a well-known risk factor for vte. about 4-6% of patients undergoing elective hepatobiliopanreatic surgery develop a deep venous thrombosis (dvt) or pulmonary embolism. however, there are no data referring to the incidence of dvt shortly ahead of the surgical event, implementing that a certain percentage of postoperative dvt might have already been acquired before the operation. furthermore, most studies only evaluate the rate of symptomatic vte. in this study, all patients undergoing hepatobiliopancreatic surgery will be screened for deep venous thrombosis the day before surgery, on the third postoperative day (primary endpoint) and 90 days after the operation with a 2-point compression sonography of the lower extremities. the development of a symptomatic vte (dvt or pulmonary embolism) will be recorded as secondary endpoint. risk factors, perioperative morbidity / mortality and presence of circulating tumor cells will be analyzed with regard to vte incidence.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective oncological liver or pancreatic resection * age equal or greater than 18 years * written informed consent exclusion criteria: * preexistent coagulopathy * history of previous vte * benign disease
hyperthyroidism: methimazole plus l-carnitine and selenium

Conditions: Hyperthyroidism

Summary: the study aims to investigate the benefits of methimazole treatment in patients with hyperthyroidism, associated with supplementation of l-carnitine and selenium.


Eligibility criteria:
inclusion criteria: * diagnosis of hyperthyroidism requiring therapy with methimazole exclusion criteria: * drug and alcohol abuse; * pregnancy; * medically uncontrolled psychiatric conditions; * interfering therapies (lithium, interferone, tki, amiodarone)